secwatch.observer — SEC 8-K summary
======================================

Issuer:     ZEVRA THERAPEUTICS, INC. (ZVRA)
CIK:        0001434647
Form:       8-K
Filed at:   2023-08-14T23:59:59+00:00
Accession:  0001437749-23-023412
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Q2 revenue $8.5M, net loss $5.1M; arimoclomol NDA resubmission on track for Q4 2023
--------------------------------------------------------------------------------

- Net revenue $8.5M in Q2 2023 vs $1.3M YoY, driven by $5M AZSTARYS milestone and royalties.
- Net loss $5.1M ($0.15/share) vs $24.0M ($0.70) in Q2 2022; prior year included $17.7M acquired IPR&D charge.
- Cash $87.4M as of June 30, 2023, supporting operations into 2026; $5M milestone received after quarter-end.
- Pre-submission meeting with FDA for arimoclomol NDA completed; resubmission expected Q4 2023.
- Phase 2 KP1077 IH trial enrolling; interim data expected Q3 2023; topline data H1 2024; narcolepsy IND opened.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1434647/000143774923023412/0001437749-23-023412-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1434647/000143774923023412/zvra20230519_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-23-023412

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer